Is Fulvic Acid Effective?
The health benefits of humic and fulvic acid have been known for many years. Fulvic Acid has been used for various conditions. But what makes CHD-FA™ better than other environmental fulvic acids?
The health benefits of humic and fulvic acid have been known for many years. Fulvic Acid has been used for various conditions. But what makes CHD-FA™ better than other environmental fulvic acids?
For over 2 decades, Fulhold Pharma Ltd the ultimate holding company of Fulvimed, has conducted extensive studies at world-renowned medical institutions specifically regarding the efficacy of CHD-FA™. The aim was to rely on proven supporting data instead of anecdotal data and general information. Is Fulvic Acid effective? Yes, CHD-FA™ is effective, safe and tested.
CHD-FA™ inhibits Carrageen-induced inflammation and enhances wound healing. This peer-reviewed published study conducted at the University of Pretoria indicated that CHD-FA™ has its anti-inflammatory effect by neutralising free radicals. The rate of reduction in the inflammation as a result of ingesting CHD-FA™ is equivalent to that of Indomethacin, a registered anti-inflammatory often used.
Phase 1 clinical study of the acute and sub-acute safety and proof of concept efficacy in humans. This peer-reviewed published study also proved that CHD-FA™ acts as an anti-inflammatory.
Inflammatory efficacy of CHD-FA™ in an in vitro whole blood assay (human). The conclusion of this study done at Washington Biotechnology was that CHD-FA™ is a potent anti-inflammatory agent comparable to Dexamethasone.
In a randomized, parallel-group, double-blind, controlled study to evaluate the efficacy and safety of CHD-FA™ in the topical treatment of eczema which was peer-reviewed and published it was found that CHD-FA™ in a cream formulation successfully improved eczema condition.
CHD-FA™ is a highly promising topical agent to enhance healing of wounds infected with drug-resistant pathogens. This peer-reviewed and published work was done at Public Health Research Institute Rutgers-New Jersey Medical School. The study proved that CHD-FA™ is effective against the ‘super-bug’, methicillin-resistant Staphylococcus aureus, a powerful microbe that has become a major concern worldwide.
Biological properties of CHD-FA™ as a potential novel therapy for the management of oral biofilm infections. This work is done at the world-famous Glasgow Dental School, School of Medicines that was peer-reviewed and published. This study concluded that CHD-FA™ exhibits broad-spectrum antimicrobial activity against orally-relevant biofilm organisms.
Synergistic effect of CHD-FA™. The results of this study conducted at the University of Pretoria showed that CHD-FA™ has antimicrobial activity against Staphylococcus aureus, multidrug-resistant Staphylococcus aureus (MRSA), Escherichia coli, Pseudomonas aeruginosa and Candida albicans. The antimicrobial spectrum of CHD-FA™ compares favourably with that of currently prescribed antibiotics and acts synergistically with oxacillin (methicillin) and gentamicin. A Gram stain of C. albicans grown in the presence of CHD-FA™ showed rounded enlarged non-dividing bodies indicating that this product acts on the cell wall of microorganisms.
Assessment of the in vitro efficacy of CHD-FA ± Oxacillin following several passages in methicillin-resistant Staphylococcus aureus (EMRSA16). This study at EuproTec in the UK indicated that there is no resistance build-up by CHD-FA™.
Determination of the in vitro efficacy of CHD-FA™ against Multi-Resistant Enterobacteriaceae and Mycobacteria. The study concluded:
CHD-FA™ was effective against NDM-1, KPC and ESBL positive Klebsiella pneumonia and multi-resistant E. coli strains with a 100% MIC value of 0.06-0.12%.
CHD-FA™ was highly effective against multi-resistant Gram-negative bacilli including NDM-1 positive strains. CHD-FA was also highly effective against Mycobacterium smegmatis. All organisms were inhibited using ≤0.12% of CHD-FA™.
Assessment of the in vivo efficacy of CHD-FA™ in a murine model of disseminated candidiasis. This study done at Euprotec in the UK proved that CHD-FA™ is effective in vivo against Candida Albicans on its own or in combination with other medicines such as Fluconazole.
Assessment of the in vitro efficacy of CHD-FA™ against Malassezia and dermatophyte isolates. This study done at Euprotec in the UK proved that CHD-FA™:
inhibits the growth of Malassezia dermatitis, Malassezia furfur and Malassezia globosa when used as a 0.125% solution at its native pH of 2.1 in vitro.
inhibits the growth of all dermatophyte strains tested, except Microsporum canis, when used as a 0.2-0.4% solution
The antioxidant properties are well-documented in general literature such as the article in the Journal of Food, Agriculture & Environment Vol. 9 (3&4): 1 2 3 – 1 2 7 . 2 0 1 1. Testing was also done on CHD-FA™ confirming its excellent antioxidant properties. The summary of work done at the University of Pretoria said: In conclusion, it has been shown that CHD-FA™ possesses some antioxidant properties in vitro.
CHD-FA™ assist in nutritional uptake as has been proven by a study at the University of Pretoria. From the study, it is clear that CHD-FA™ will assist in the nutritional uptake of various minerals.
Because of the properties of CHD-FA™, it essentially acts as its own preservative in various products. The preservative efficacy report by SWIFT SILLIKER confirms the preservative properties of CHD-FA™.